Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis
Background: To date, no consistent data are available on the possible impact of CFTR modulators on glucose metabolism. The aim of this study was to test the hypothesis that treatment with CFTR modulators is associated with an improvement in the key direct determinants of glucose regulation in children and young adults affected by Cystic Fibrosis (CF). Methods: In this study, 21 CF patients aged 10–25 underwent oral glucose tolerance test (OGTT) before and after 12–18 months of treatment with Lumacaftor/Ivacaftor or Elexacaftor-Ivacaftor-Tezacaftor. β-cell function (i.e., first and second phase of insulin secretion measured as derivative and proportional control, respectively) and insulin clearance were estimated by OGTT mathematical modelling. Insulin sensitivity was estimated by the Oral Glucose Sensitivity Index (OGIS). The dynamic interplay between β-cell function, insulin clearance and insulin sensitivity was analysed by vector plots of glucose-stimulated insulin bioavailability vs. insulin sensitivity. Results: No changes in glucose tolerance occurred after either treatment, whereas a significant improvement in pulmonary function and chronic bacterial infection was observed. Beta cell function and insulin clearance did not change in both treatment groups. Insulin sensitivity worsened in the Lumacaftor/Ivacaftor group. The analysis of vector plots confirmed that glucose regulation was stable in both groups. Conclusions: Treatment of CF patients with CFTR modulators does not significantly ameliorate glucose homeostasis and/or any of its direct determinants..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 11(2022), 14, p 4149 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Claudia Piona [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Cftr modulators |
|---|
| doi: |
10.3390/jcm11144149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030849330 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030849330 | ||
| 003 | DE-627 | ||
| 005 | 20240414071007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11144149 |2 doi | |
| 035 | |a (DE-627)DOAJ030849330 | ||
| 035 | |a (DE-599)DOAJ404d4522c5764f43998247365044e474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Claudia Piona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: To date, no consistent data are available on the possible impact of CFTR modulators on glucose metabolism. The aim of this study was to test the hypothesis that treatment with CFTR modulators is associated with an improvement in the key direct determinants of glucose regulation in children and young adults affected by Cystic Fibrosis (CF). Methods: In this study, 21 CF patients aged 10–25 underwent oral glucose tolerance test (OGTT) before and after 12–18 months of treatment with Lumacaftor/Ivacaftor or Elexacaftor-Ivacaftor-Tezacaftor. β-cell function (i.e., first and second phase of insulin secretion measured as derivative and proportional control, respectively) and insulin clearance were estimated by OGTT mathematical modelling. Insulin sensitivity was estimated by the Oral Glucose Sensitivity Index (OGIS). The dynamic interplay between β-cell function, insulin clearance and insulin sensitivity was analysed by vector plots of glucose-stimulated insulin bioavailability vs. insulin sensitivity. Results: No changes in glucose tolerance occurred after either treatment, whereas a significant improvement in pulmonary function and chronic bacterial infection was observed. Beta cell function and insulin clearance did not change in both treatment groups. Insulin sensitivity worsened in the Lumacaftor/Ivacaftor group. The analysis of vector plots confirmed that glucose regulation was stable in both groups. Conclusions: Treatment of CF patients with CFTR modulators does not significantly ameliorate glucose homeostasis and/or any of its direct determinants. | ||
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a cftr modulators | |
| 650 | 4 | |a lumacaftor/ivacaftor | |
| 650 | 4 | |a elexacaftor-ivacaftor-tezacaftor | |
| 650 | 4 | |a oral glucose tolerance test | |
| 650 | 4 | |a glucose metabolism | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Enza Mozzillo |e verfasserin |4 aut | |
| 700 | 0 | |a Antonella Tosco |e verfasserin |4 aut | |
| 700 | 0 | |a Sonia Volpi |e verfasserin |4 aut | |
| 700 | 0 | |a Francesco Maria Rosanio |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Cimbalo |e verfasserin |4 aut | |
| 700 | 0 | |a Adriana Franzese |e verfasserin |4 aut | |
| 700 | 0 | |a Valeria Raia |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Zusi |e verfasserin |4 aut | |
| 700 | 0 | |a Federica Emiliani |e verfasserin |4 aut | |
| 700 | 0 | |a Maria Linda Boselli |e verfasserin |4 aut | |
| 700 | 0 | |a Maddalena Trombetta |e verfasserin |4 aut | |
| 700 | 0 | |a Riccardo Crocina Bonadonna |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Cipolli |e verfasserin |4 aut | |
| 700 | 0 | |a Claudio Maffeis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 11(2022), 14, p 4149 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:14, p 4149 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm11144149 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/404d4522c5764f43998247365044e474 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/11/14/4149 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 14, p 4149 | ||